SION-638 is under clinical development by Sionna Therapeutics and currently in Phase I for Cystic Fibrosis. According to GlobalData, Phase I drugs for Cystic Fibrosis have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SION-638’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SION-638 overview

SION-638 is under development for the treatment of cystic fibrosis (CF) with F508del genetic mutations. The therapeutic candidate is a small molecule that acts by targeting the nucleotide-binding domain (NBD1) of cystic fibrosis transmembrane conductance regulator (CFTR).

Sionna Therapeutics overview

Sionna Therapeutics (Sionna) is a developer of novel small molecule therapies to treat cystic fibrosis (CF). Sionna is headquartered in Natick, Massachusetts, the US.

For a complete picture of SION-638’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.